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ABSTRACT 
Objective: In the domain of nano drug delivery, dendrimers are the most explored bioactive polymeric carrier system. The present work was aimed 
to study the diffusion potential of different generations of Poly (propyleneimine) (PPI) dendrimers on goat nasal mucosa in an ex vivo study and 
synthesize a stable dendrimer for olfactory drug delivery. 
Methods: The generations (3.0G, 4.0G, and 5.0G) of PPI dendrimer were synthesized, and PEGylated by MPEG 5000 and then loaded with donepezil. 
A comparative study was carried out among all generations in term of their drug loading capacity, stability, sustained release behaviour as well as 
for targeting efficacy. An ex-vivo study was carried out on Franz Diffusion Cell with goat nasal mucosa. 
Results: The developed G3, G4, and G5 dendrimerformulations had entrapment efficiency of 24.33±0.56%, 40.12±0.62%, and 60.4±0.6%, 
respectively. The nasal diffusion study revealed that 5.0G PPI dendrimer increased diffusion of donepezil up to 47% as compared to the pure 
solution of donepezil while 10% improvement in diffusion was seen as compared to 4.0 G PPI dendrimer. Thus obtained results claimed that the 
drug loading as well as targeting potential of PPI dendrimers increased with the increase in the number of generation. The investigation outcome 
indicated promising results of 5.0G PPI dendrimer over the 3.0G and 4.0G PPI dendrimer generations for their drug loading capacity, stability, and 
sustained release action. 
Conclusion: The 5.0G PPI dendrimer proved its superior candidature over the other lower generations of PPI dendrimers for drug delivery and 
drug targeting.  
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A drug delivery system administers therapeutic agents in the body. 
The delivery system changes pharmacokinetic as well as 
pharmacodynamic behaviour of therapeutics and enhances its 
pharmacological activities provide maximum benefits. By size, nature 
and sources the drug delivery system may have various devices for 
administration. Similarly, the traditional drug delivery system has 
various agents like micro-emulsion, tablets, capsules, ointments, 
microparticles and multiple emulsions depending on their size [1-3]. 
In the present arena, nanotechnology offers exquisite approaches 
such as nanoparticles, dendrimers, liposomes and carbon nanotubes 
etc [4, 5]. The nanocarriers may be easily validated and designed with 
defined size, shape and surface charge etc. and claim their potential in 
targeted as well as controlled drug delivery. 
Dendrimers are most widely explored polymeric nanocarrier system 
among the existing polymeric nanocarriers [6, 7]. The dendrimer is 
three dimensional highly branched, synthetic, well defined, spherical 
structure (size of 1-100 nm) mono dispersible polymeric system [8, 
9]. Dendrimers have various exclusive characteristics including their 
modifiable surface functionality, mono-dispersity along with highly 
defined nano-dimensional spherical architecture. Dendrimers 
contain a large number of hydrophobic cavities in its nano-scale 
domain and offer controlled as well as sustained drug release action 
by entrapping therapeutics in these cavities [10, 11]. 
 
 
Fig. 1: Different generations of dendrimers (PPI) 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 10, Issue 12, 2018 
Shah et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 12, 80-87 
 
81 
Dendrimers contain three distinct regions in their architecture 
including core, branches and peripheral functional groups. The core of 
dendrimers comprises an atomic group with two or more identical 
chemical functions while branches derive from core and wrapping of 
these branching units organize a geometrical progression of a 
sequence of radially concentric coats called "generations" (fig. 1,) [12, 
13]. Repetition of branching layers leads to subsequent higher 
generations. With each consequential generation the number of 
terminal groups increases exponentially. In dendrimers, successive 
addition of each layer gradually increases diameter as well as 
molecular size with amplification of terminal groups. 
The present study investigates the targeting potential as well as 
biocompatibility of different generations of PPI dendrimers. Various 
parameters related to drug delivery, i.e., drug loading capacities, 
release behaviours, stability diffusion potential through goat nasal 
mucosa profile at different concentration and histopathological 
evaluation was undertaken. This research work will help the drug 
delivery researchers for the selection of optimized PPI dendrimeric 
generation concerning their drug delivery as well as toxicological 
aptitudes.  
MATERIALS AND METHODS 
Materials 
Acrylonitrile (ACN) and ethylenediamine (EDTA) were purchased from 
CDH (India). Raney nickel was purchased from Fluka (USA). Mono 
methoxy polyethylene glycol 5000 (MPEG-5000) was arranged from 
Sigma Chemicals. N,N'-Dicyclohexylcarbodiimide (DCC), was brought 
from Hi-Media Lab. (Mumbai, India). MTT [3-(4,5-dimethyl thiazolyl-2)-
2,5 diphenyltetrazolium bromide] was purchased from Sigma Aldrich 
(USA). Analytical grade reagents were purchased from Merck India Ltd. 
Donepezil HCl was received as gift samples from Sun Pharmaceuticals 
Ltd. (Vadodara, India). 
Goat nasal mucosa was arranged from registered slaughterhouse 
Ahmadabad Municipal Corporation. 
Synthesis of PPI dendrimers of different generations 
3.0G, 4.0G, and 5.0G dendrimers were synthesized using different 
methods [14-17]. In the synthesized dendrimeric generations, EDTA 
constituted the inner core while acrylonitrile made branches of the 
dendrimers. Detailed synthesis is shown in fig. 2. 
  
 
Fig. 2: Scheme of synthesis of different generation of PPI dendrimers 
 
Half generation of PPI dendrimer was produced by addition of 
acrylonitrile in aqueous EDTA solution by double Michel 
addition reaction. This reaction was exothermic in which the 
temperature was increased from 38 °C to 80 °C and was 
maintained during the whole reaction. This resultant half 
generation PPI dendrimer had–CN terminated ends. Then, it was 
subjected to heterogeneous hydrogenation with catalyst Raney 
Nickel to synthesize a PPI dendrimer of the full generation 
having amine terminated ends. The whole process involving the 
addition of acrylonitrile and subsequent hydrogenation was 
repeated till 5G PPI dendrimer was synthesized. The synthesized 
generations of PPI dendrimers were subjected to structure 
elucidation, FT-IR and H1-NMR spectroscopy followed by 
microscopical examination using transmission electron 
microscopy.  
PEGylation 
The PEGylation of the developed formulation was carried out using 
NHS ester derivative of MPEG-5000 as per the scheme depicted in 
fig. 3. MPEG 5000 was converted in carboxy derivative in the 
presence of DCC into an ester derivative. The activated MPEG NHS 
ester interacted with terminal NH2 endings of dendrimer and 
masked all the open amino ends and thus leading to the 
development of biocompatible formulations. 
All the developed formulations of G3, G4 and G5 dendrimer (1 mg 
for each) were dissolved in double distilled water. Then the 
activated MPEG NHS ester (0.32 mmol) solution was added in the 
0.01 mmol solution of G3, G4 and G5 PPI dendrimeric formulations 
in dimethyl sulfoxide(DMS), and allowed for stirring at room 
temperature for five days separately. The obtained products were 
lyophilized and concentrated [18, 19]. All PEGylated PPI 
dendrimeric formulations were characterized using FT-IR and H1 
NMR spectroscopy.  
Drug loading 
A known concentration of donepezil HCl (247.5 mg, 12 mmol) was 
dissolved in 50 ml of 6.4 pH of PBS buffer was slowly added with 
stirring and stirred for 15 min with a Teflon® bead. Then 1% 
solution (10 mg per ml) of each PEGylated 3G, 4G and 5G PPI 
dendrimers were prepared and 2 ml of this solution was dialyzed in 
dialysis membrane (MW Cut-off [MWCO] 6,000-7,000 Da, Sigma) 
with 50 ml of 6.4 pH of PBS buffer solution on 50 rpm for 24h for 
encapsulation of donepezil to PPI dendrimers (fig. 4). 
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Fig. 3: Scheme of PEGylation of different generation of PPI dendrimer 
  
 
Fig. 4: Process of donepezil HCl loading to different dendrimeric generations 
 
The resulting solution was dialyzed twice through a cellulose 
dialysis bag (molecular weight cut-off: 3.5 kDa; Sigma-Aldrich) 
against double-distilled water under strict sink conditions for 30 
min to remove the free drug from the formulation. The obtained 
formulations of donepezil loaded, 3.0G PPI (G3PPID), 4.0G PPI 
(G4PPID) and 5.0G PPI (G5PPID) dendrimers were estimated by 
HPLC method using mobile-phase methanol: acetonitrile: acetate 
Buffer (1%) (50: 20: 30) pumped onto the Agispack® C18, (150 X 
4.6 mm) column at a flow rate of 1 ml/min. The analysis was carried 
out at 230 nm [20] to determine the amount of drug loaded within 
the formulations indirectly.  
Characterization of donepezil HCl loaded PPI dendrimers 
The synthesized PPI dendrimers were characterized by FT-IR, 1H-
NMR and Transmission electron microscopy. 
% Entrapment efficacy (EE) 
The % entrapment efficacy of formulated G3PPID, G4PPID and 
G5PPIDdendrimers was determined by centrifugation method. Two 
ml of the dendrimer-donepezil complex was taken and separately 
dialyzed using the dialysis membrane (MW Cut-off [MWCO] 6,000-
7,000 Da, Sigma) against 50 ml double distilled deionized water 
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(DDW) for 15 min. One ml of DDW was withdrawn in a 10 ml 
volumetric flask, and the volume was made up to 10 ml with fresh 
DDW. The absorbance was noted at 230 nm and was used to 
evaluate the unentrapped drug. Further, the quantity of the drug 
entrapped was assessed. %EE was calculated by the following 
equation:  
%EE= Total amount of donepezil−Amount of Free donepezil 
Total amount of donepezil 
 X100 
In vitro release study 
To monitor the release of donepezil from different drug-dendrimer 
formulations, 5 ml of each G3PPID, G4PPID, and G5PPID (2 mg/ml) 
was taken in cellulose membrane (3.5 kDa, Sigma, USA). This bag 
was placed in a 100 ml release medium comprising of phosphate 
buffer saline (PBS) 0.1M, pH 7.4 (medium-1), 0.1 M phosphate buffer 
(pH 7.4)+1% Albumin (medium-2), phosphate buffer 0.1 M, pH 6.4 
(medium-3) and DDW alone under sink conditions in the receptor 
compartment through constant stirring (200 rpm using magnetic 
stirrer) at room temperature adjusted to 37 °C. 
A half milliliter of each formulation release medium was withdrawn 
at predetermined time intervals from 0.5 h to 48 h. After the 
withdrawal, the release medium was replaced with an equal volume 
of fresh medium, and the sink conditions were maintained. Then the 
collected samples were estimated by HPLC and release of donepezil 
content was determined [17]. All these experiments were performed 
in triplicate, and the obtained results were presented as the 
mean±standard deviation. 
Stability studies 
Stability studies were carried out for the development of a safe and 
stable formulation, which is the primary requirement of the 
pharmaceutical industry. During the development of stable dosage 
forms, confirmation of specific physicochemical parameters have been 
proved to be of considerable advantage in the performance of stability 
studies. The stability studies explore the most stable storage conditions 
for the developed dendrimeric formulations regarding drug delivery. 
The developed G3PPID, G4PPID, and G5PPID dendrimeric 
formulations were weighed up to the amount (5 ml), were stored at 
various temperature conditions (0˚C, room temperature, and 50˚C), 
and were kept in light (colorless vials) and dark (amber color bottle) 
in the controlled environment for ten months. During the storage 
period, all the formulations were investigated every week for 
turbidity, precipitation, crystallization, drug leakage and colour. 
Nasal diffusion studies 
Nasal diffusion study was carried out using Franz diffusion cell 
(Orchid Scientifics). The diffusion cell has a receptor chamber of 10 
ml capacity, and the donor compartment is of 0.5 ml capacity. The 
goat nasal mucosa was used as dialyzing membrane while pH 6.4 
phosphate buffer saline (PBS) as receptor medium. A fresh goat 
nasal mucosa was isolated from goat nasal part and rinsed with PBS. 
The nasal mucosa of the thickness of 3 mm was knitted on diffusion 
cell as mucosal part facing on donor compartment while serosal part 
was facing on the receptor chamber. The nasal diffusion experiment 
was carried out in triplicate for G4PPID, G5PPID and simple solution 
of donepezil (5 mg/ml). The receptor chamber was filled with 6.4pH 
PBS and was subjected to stirring using a magnetic bead in a manner 
so that the PBS touched the serosal surface of the nasal mucosa. The 
vitality of nasal mucosa was maintained by providing oxygen supply 
with the help of laboratory aerator (Elite 80) and keeping the 
temperature at 37±1◦C w ith the circulating water bath. Then 
aliquots of 1 ml volume were withdrawn at 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 
h, and 12 h from receptor chamber and the volume of receptor 
chamber was maintained by replacing an equal amount of PBS. The 
collected samples were estimated for drug content using HPLC at 
230 nm.  
Nasal histopathology 
The histopathological studies of nasal mucosa were performed to 
determine the biocompatibility of the developed formulations of 
G4PPID and G5PPID on the nasal mucosa. Five samples of goat nasal 
mucosa of even thickness (0.3 mm) were subjected to the 
investigation of any pathological changes produced by developed 
formulations. The first sample was positive control and treated with 
isopropyl alcohol for 1 h. The second sample was negative control 
and was treated with only PBS pH 6.4 for 1h. Besides this, third, 
fourth and fifth samples were treated with G4PPID, G5PPID and 
simple donepezil solution respectively in the concentration of 5 
mg/ml for 1 h. 
After the treatment, all nasal mucosa samples were washed with PBS 
buffer (pH 6.4) and fixed into 10% v/v formalin solution for 12 h. All 
five samples of nasal mucosa were subjected to histopathological 
studies using hematoxylin and eosin stain and were examined under 
an inverted microscope (Olympus-IX51) to estimate any damage to 
nasal mucosa. 
RESULTS AND DISCUSSION 
Synthesis and characterization of PPI dendrimers 
Dendrimers were synthesized as per established protocol reported, 
with the use of EDTA as core and acrylonitrile for branching 
material. FT-IR and 1H-NMR spectroscopic methods wereused to 
confirm the synthesis of every generation and elucidate the 
structure of synthesized dendrimeric generation. Transmission 
electron microscopy images indicated that the size of dendrimer 
increased proportionately with the increase in generation number 
(fig. 5A, 5B and 5C). 
As per reported procedure of De Brabender Van Den Berg [8, 14], 
different generations of PPI dendrimers were synthesized in 
ethylenediamine used as initiator core. Synthesis of 0.5G PPI was 
confirmed by a strong IR peak of nitrile at 2248 cm-1. On 
hydrogenation all the nitrile terminal, 0.5G PPI got converted to 
(NH2)4, which was confirmed by IR of PPI 1.0G that exhibited major 
peak at 3374 cm-1 for amine (N-H stretch). Similarly, synthesis of 
5.0G PPI dendrimers was also confirmed from different IR peaks. 
The main peaks were CH2 rocking (766.7 cm-1); C-N stretching of 
CH2-NH2, (1118.3 cm-1); CH2 scissoring (1382.3 cm-1, 1463.9 cm-1); 
N-H bending (scissoring) vibrations (1597 cm-1) and primary amine 
at 3397 cm-1
 
 (N-H stretch), confirming that nitrile terminal groups of 
dendrimer were converted to amine terminals. The results matched 
with the reported synthesis of PPI dendrimers [15, 16]. 
 
5A 
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Fig. 5A: IR spectra of 5.0G PPI dendrimer, 5 B. NMR Spectra of 5.0G PPI dendrimer, 5C. TEM of 5.0G PPI dendrimer 
 
Characterization of PEGlated PPI dendrimers 
The synthesized different generations of PPI dendrimers were 
PEGylated with MPEG-5000 and DCC. The obtained IR and NMR 
spectroscopic data confirmed the PEGylation of different 
generations of PPI dendrimers. The IR spectrum of 5.0G PPI 
dendrimer exhibited a major peak at 1254.9 cm-1of an ether linkage 
(CO), and the peak at 3420.4 cm-1 indicated the N-H stretching of the 
amide. A significant IR peak found near to 1657.3 cm-1, certified the 
C=O stretch of amide group of PEGylated dendrimers. The critical 
peak of CN stretch of amide also appeared at 2920.6 cm-1as shown in 
fig. 6A. The difference in NMR spectrum (fig. 6B) as well as the shifts 
of PEGylated dendrimers as compared to the same generation 
simple dendrimers confirmed the PEGylation. On PEGylation, some 
increase in integral value was found due to secondary CH2 groups 
shift. PEGylation of5.0G PPI dendrimer led to the rise in the numbers 
of secondary CH2
  
 groups and thus, causing forward direction shift in 
NMR spectra. The sharp peak observed at 3.4e, and 3.6 ppm in 
spectra was due to the presence of ether linkages which appeared 
after PEGylation. The characteristic peak of amide linkage appeared 
near 7.82 ppm in NMR spectrum of PEGylated dendrimers as shown 





Fig. 6A: IR spectra of PEGlated 5.0G PPI dendrimer, 6B. NMR Spectra of PEGlated 5.0G PPI dendrimer 
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Equilibrium dialysis technique was applied to encapsulate donepezil 
inside the dendrimer. PPI dendrimers indicated 24.33±0.56%, 
40.12±0.62% and 60.4±0.6%,drug loading for G3PPID, G4PPID, and 
G5PPIDdendrimer respectively (fig. 7). Non-covalent interactions 
between donepezil and dendritic formulations, such as hydrogen 
bonding and hydrophobic interaction may be ascribed to the 
physical entrapment of donepezil molecules. Amount of drug loading 
was increased with higher dendrimeric generations. 
 
 
Fig. 7: Entrapment efficiency percentages (for donepezil HCl) of 
different generations of PPI dendrimers 
 
In vitro drug release study 
The rate of drug release of the formulation was observed in various 
media and can be suggested for the controlled release drug delivery 
system. A higher release was found in phosphate buffer (pH 6.4) 
because the amine groups protonate at this pH, causing them to 
repel each other exposing the drug to the media. This release can be 
beneficial because of simulated pH condition on the nasal mucosal 
site as well as on neuronal parts of the brain, enhancing the chances 
of drug delivery to these sites. A nonlinear drug release profile was 
obtained when all the developed formulations were subjected for 
drug release study in the different medium. Initially, the formulation 
indicated a fast release of drug at first two 2-4 hr followed by which 
a sustained release action was observed. The dendrimer 
encapsulated drug molecules into their hydrophobic pockets and 
behaved as a sink and released the drug molecules for an extended 
duration rather than surface molecules of dendrimers. The higher 
generations of dendrimer indicated a higher intensity of controlled 
or sustained release in comparison to lower dendrimeric 
generations. A possible mechanism postulated for the sustained 
release action of higher dendrimeric generations is that, in the 
higher generations, the encapsulated drug molecules have to travel 
more distance to reach outer medium in comparison to lower 
dendrimeric generation. Another reason for sustained drug release 
action of a higher generation of PPI dendrimer is that the higher 
generation dendrimers have many layers of hydrophobic cavities for 
drug encapsulation surrounding the core and each layer generation 




Fig. 8: Cumulative release percentage of donepezil HCl from 
5.0G PPI dendrimer 
Stability studies 
Different physical parameters like precipitation, crystallization, 
colour, drug release, and turbidity were observed at different 
temperature and storage conditions during stability monitoring of 
different generations of PPI dendrimer. Under all circumstances, the 
G5PPID dendrimers were found to be most stable as compared to 
other generations. All the formulations indicated maximum stability 
at room temperature and in dark storage conditions. Thus, all the 
formulations displayed a temperature dependent drug leakage and 
storing the formulation under investigation at room temperature in 
the dark was the ideal storage condition for all dendrimeric 
formulations. 
The G3 PPID indicated maximum drug leakage in comparison to 
higher generation due to its smaller size, but on the other side, that 
was unable to hold a high amount of drug. Generally, the lower 
generations have a low intensity of layer resistance for drug release 
or drug leakage and thus are expected candidates for easy drug 
release. While as the generations increase, proportionately the layer 
resistance for drug leakage also increase. Thus, confirming our data 
that the higher generation dendrimer was the most versatile.  
Nasal diffusion studies  
Nasal diffusion studies were carried out with goat nasal mucosa as 
an alternative to the human nasal mucosa and compared the 
percentage of drug diffusion which is targeted through G4PPID, 
G5PPID, and pure donepezil. The amount of drug which diffused 
(percentage) versus time was compared at all-time points (0.5, 1, 2, 
4, 6, 8 and 12 hr). G5PPID diffused more considerable amount of 
donepezil as compared to G4PPID and pure donepezil. At 6 hr, G5PPI 
diffused up to 74.33% of donepezil. At the same time point, G4PPI 
diffused 48.53% of donepezil while pure donepezil diffused up to 
23.20%. After 8 hrG5PPID diffused 97.19 %of donepezil as 
compared to G4PPIDwhich diffused 89.81% of donepezil and 
50.44% of donepezil diffused from simple donepezil solution. Thus, 
G5PPID enhanced 47% of drug diffusion through nasal mucosa as 
compared to pure drug and 10% from G4PPID (fig. 9) [21]. 
 
 
Fig. 9: Nasal diffusion of donepezil from PBS pH 6.4, G4 and G5 
PPI dendrimer in the PBS solution 
 
The possible mechanism postulated may be that the dendrimer 
contained positively charged amino groups at terminal ends which 
interacted with the negatively charged sialic acid of nasal mucosal 
cell membranes and opened the tight junctions of mucosal 
membranes thus increased the drug permeation across the surface 
of nasal mucosa [22]. 
Nasal histopathology 
Nasal histopathology was carried out to determine the possible toxic 
effects of the developed formulation on the surface of the nasal 
mucosa. Fig. 10 represents five different representative images of 
sections of nasal mucosa viz., (A) positive control treated, (B) 
negative control treated, (C) mucosa treated with G5PPID, (D) nasal 
mucosa treated with G4PPID and (E) nasal mucosa treated with pure 
donepezil. In the negative control group, nasal mucosa was found to 
be extensively damaged on the epithelial surface and an internal 
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tissue treated with isopropyl alcohol. The positive control was 
treated with PBS pH 6.4 and was found to be intact with preserved 
structure. In the nasal mucosal sections treated with G4PPID and 
G5PPID, neither structural damage nor cell necrosis was 
represented and stabilized their biocompatibility. These 
observations were following the pH value of G4PPID and G5PPID 
(5.87±0.11) which was within the pH range of human nasal mucosa 
(5–6.5) indicating its safety for nasal administration [23]. 
 
   
A B C 
  
D E 
Fig. 10: Photomicrograph of sections of goat nasal mucosa of (A) positive control group, (B) negative control (C) G5PPID (D) G4PPID and 
(E) pure donepezil treated (magnification: 400X) 
 
CONCLUSION 
The obtained results are suggestive that the PEGylated 5.0G 
dendrimer is most stable dendrimer with greatest entrapment 
efficacy for donepezil as compared to other lower generations of 
3.0G and 4.0G PPI dendrimers. Successful nasal diffusion of the 
developed formulations offer olfactory administration and eliminate 
the possibility of the spill over effect of the drug from first pass 
metabolism as well as transportation from the blood-brain barrier. 
The 5.0G PPI dendrimer has numerous amino groups on the external 
surface as compared to other lower generations and thus, is the 
most suitable dendrimer for drug targeting due to greatest chances 
of surface engineering. Besides, 5.0G PPI dendrimers have a large 
number of cavities in its skeleton, proposed higher drug loading and 
greatest sustained released behaviour. Conclusively, 5.0 G PPI 
dendrimer indicate likely candidature for drug loading, stability, 
drug release and nasal diffusion over the 3.0G and 4.0G of PPI 
dendrimers.  
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